Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Food Effect of THB335 in Healthy Participants

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Food Effect of THB335 in Healthy Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs THB 335 (Primary)
  • Indications Inflammation
  • Focus Adverse reactions
  • Sponsors Third Harmonic Bio

Most Recent Events

  • 12 Jun 2025 According to a Third Harmonic Bio media release, the Company recently completed an additional 14-day multiple ascending dose cohort (n=10) in the Phase 1 clinical trial of THB335 in healthy volunteers
  • 11 Feb 2025 According to a Third Harmonic Bio media release, The full Phase 1 clinical results will be presented as a poster presentation at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress on Sunday, March 2, 2025, at 9:45 a.m. PST.
  • 11 Feb 2025 According to a Third Harmonic Bio media release, company expects data from this study to support the advancement of THB335 into a Phase 2 clinical trial in chronic spontaneous urticaria (CSU).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top